XENON PHARMACEUTICALS INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- XENON PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $699.00K, a 2396.43% increase year-over-year.
- XENON PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $28.00K.
- XENON PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $111.00K, a 382.61% increase year-over-year.
- XENON PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $106.00K, a 657.14% increase year-over-year.
- XENON PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2024 was $47.00K, a 34.29% increase from fiscal 2023.
- XENON PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2023 was $35.00K, a 95.04% decline from fiscal 2022.
- XENON PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2022 was $705.00K, a 171.15% increase from fiscal 2021.
- XENON PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2021 was $260.00K, a 217.07% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-12-31 | $47.00K 10-K · filed 2025-02-27 | |
| 2023-12-31 | $35.00K 10-K · filed 2025-02-27 | |
| 2022-12-31 | $705.00K 10-K · filed 2025-02-27 | |
| 2022-09-30 | $699.00K 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $260.00K 10-K · filed 2024-02-29 | |
| 2021-09-30 | $28.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $111.00K 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $106.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $82.00K 10-K · filed 2023-03-01 | |
| 2020-06-30 | $23.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $14.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $122.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $18.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $11.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $58.00K 10-Q · filed 2020-11-05 | |
| 2018-09-30 | $80.00K 10-Q · filed 2019-11-05 | $262.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $63.00K 10-Q · filed 2019-11-05 | $182.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-03-31 | $119.00K 10-Q · filed 2019-11-05 | $122.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $177.00K 10-K · filed 2019-03-06 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $225.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $227.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-03-31 | $174.00K 10-Q · filed 2017-05-09 | $262.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $132.00K 10-K · filed 2018-03-07 |
| 2016-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $122.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $147.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $44.00K 10-Q · filed 2016-05-10 | $195.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $278.00K 10-K · filed 2018-03-07 |
| 2015-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $243.00K derived: sum of 4 quarters · filed 2017-03-08 |
| 2015-06-30 | $86.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2015-08-13 | |
| 2015-03-31 | $127.00K 10-Q/A · filed 2015-08-13 | |
| 2014-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $13.00K 10-K · filed 2017-03-08 |
| 2013-12-31 | $49.00K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |